Related Experiment Video

Updated: Jul 16, 2026

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

[The metabolic syndrome in postmenopausal women. Clinical implications]

Arturo Zárate1, Lourdes Basurto, Marcelino Hernández

  • 1Unidad de Investigación Médica en Enfermedades Endocrinas, Hospital de Especialidades, Centro Médico Nacional, IMSS, México, D.F. zaratre@att.net.mx

Gaceta Medica De Mexico
|January 16, 2004
PubMed

Insights

Cardiovascular disease (CVD) risk increases in postmenopausal women due to lost estrogen protection and metabolic changes. Hormone replacement therapy (HRT) shows limited cardiovascular benefits and potential thromboembolism risks.

Area of Science:

  • Reproductive Endocrinology
  • Cardiovascular Medicine
  • Metabolic Syndrome Research

Background:

  • Postmenopausal women face increased cardiovascular disease (CVD) mortality due to loss of estrogen's protective effects.
  • Estrogen decline after menopause leads to adverse lipid profiles and elevated coagulation factors, increasing CVD risk.
  • Metabolic syndrome, characterized by multiple risk biomarkers, is a key precursor to insulin resistance, diabetes, and CVD.

Purpose of the Study:

  • To evaluate the efficacy and risks of common preventive therapies for cardiovascular diseases in postmenopausal women.
  • To assess the impact of hormone replacement therapy (HRT) on cardiovascular risk and inflammatory biomarkers.
  • To understand the relationship between metabolic syndrome, coagulation, and fibrinolysis in the context of postmenopausal CVD.

Main Methods:

  • Review of existing literature on cardiovascular disease prevention in postmenopausal women.
  • Analysis of the effects of hormone replacement therapy (HRT), including oral estrogen and transdermal estradiol, on lipid profiles, coagulation, and inflammatory markers.
  • Examination of the role of metabolic syndrome biomarkers in predicting cardiovascular risk.

Main Results:

  • Hormone replacement therapy (HRT) has not demonstrated the expected reduction in cardiovascular disease (CVD) and carries risks of thromboembolism.
  • Oral estrogen use is linked to elevated C-reactive protein and variable effects on IL-6, while transdermal estradiol shows no significant impact on these inflammatory markers.
  • No definitive evidence confirms that changes in inflammatory biomarkers due to HRT modify overall cardiovascular risk.

Conclusions:

  • The ideal hormone replacement therapy (HRT) for cardiovascular disease (CVD) prevention in postmenopausal women remains elusive.
  • The potential benefits of long-term HRT must be carefully weighed against the increased risk of thromboembolism.
  • Current evidence does not support the use of HRT based on its effects on inflammatory biomarkers for cardiovascular risk modification.

More Related Videos

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome06:04

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome

Published on: September 27, 2024

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...